Skip to main content

Table 2 Liver Steatosis and Fibrosis at baseline and by week 24

From: Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial

Variable

Pioglitazone Group

(n = 36)

Empagliflozin Group

(n = 37)

 

Baseline

After 24 weeks

P value

Baseline

After 24 weeks

P value

P value*

CAP (dB/m)

329.8 ± 19.1

304.1 ± 32.8

< 0.01

325.1 ± 18.4

276.9 ± 39.0

< 0.01

0.01

LSM (kPa)

7.2 ± 2.5

6.4 ± 1.5

0.01

7.4 ± 3.4

6.3 ± 2.4

< 0.01

0.26

  1. CAP, controlled attenuation parameter; LSM, Liver stiffness measurement
  2. *Between-group difference from baseline, P < 0.05 is significant.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us